共 50 条
- [1] Pramlintide, as an adjunct to premixed insulin, reduced A1C and body weight in patients with type 2 diabetes[J]. DIABETES, 2008, 57 : A585 - A585Lorenzi, GayleZhang, BeiDarsow, TamaraMaier, HollyWilhelm, Ken
- [2] Pramlintide, as an adjunct to premixed insulin, reduced HbA1c and body weight in patients with type 2 diabetes[J]. DIABETOLOGIA, 2008, 51 : S409 - S409Darsow, T.Lorenzi, G.Zhang, B.Maier, H.Wilhelm, K.
- [3] Pramlintide, as an adjunct to long-acting insulin, led to improved A1C and body weight in patients with type 2 diabetes[J]. DIABETES, 2006, 55 : A124 - A124Lush, CameronStrobel, SusanZhang, BeiFrias, Juan
- [4] Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2007, 9 (02) : 191 - 199Karl, DianePhilis-Tsimikas, AthenaDarsow, TamaraLorenzi, GayleKellmeyer, TerrieLutz, KarenWang, YanFrias, Juan P.
- [5] Relationship of Insulin Dose, A1c Lowering, and Weight in Type 2 Diabetes: Comparing Insulin Glargine and Insulin Detemir[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2010, 12 (12) : 1019 - 1027Dailey, GeorgeAdmane, KarimMercier, FlorenceOwens, David
- [6] rEffects of Pramlintide on A1C, Weight, and Hypoglycemia in Patients With Type 1 or Type 2 Diabetes: Subgroup Analysis by Duration of Diabetes[J]. DIABETES, 2013, 62 : A267 - A267Herrmann, KathrinBrunell, Steven C.Shan, KevinChen, Steve
- [7] Pramlintide, as an adjunct to basal insulin, reduced C-reactive protein, improved glycemic control, and led to weight loss in patients with type 2 diabetes[J]. DIABETES, 2007, 56 : A144 - A144Lush, CameronFrias, JuanZhang, BeiMaier, HollyKolterman, Orville
- [8] Effect of pramlintide on A1C and body weight in insulin-treated African Americans and hispanics with type 2 diabetes:: A pooled post hoc analysis[J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (12): : 1638 - 1642Maggs, DShen, LStrobel, SBrown, DKolterman, OWeyer, C
- [9] In an open-label clinical study pramlintide lowered A1C, body weight, and insulin use in patients with type 2 diabetes failing to achieve glycemic targets with insulin therapy[J]. DIABETES, 2005, 54 : A12 - A12Karl, DMWang, YLorenzi, GFreeman, JS
- [10] In an open-label clinical study pramlintide lowered A1C, body weight, and insulin use in patients with type 1 diabetes failing to achieve glycemic targets with insulin therapy[J]. DIABETES, 2005, 54 : A118 - A118Guthrie, RKarl, DMWang, YLorenzi, G